KDM1A Inhibitors for Disease Treatment Patent Application
Summary
The USPTO has published a new patent application (US20260085082A1) from Imago Biosciences, Inc. The application discloses new compounds and compositions for pharmaceutical use, specifically for inhibiting KDM1A and increasing gamma globin gene expression to treat diseases like acute myelogenous leukemia.
What changed
This document is a published patent application from the USPTO, detailing new compounds and compositions developed by Imago Biosciences, Inc. The application, identified as US20260085082A1, focuses on KDM1A inhibitors for pharmaceutical applications, including methods for treating diseases such as acute myelogenous leukemia by increasing gamma globin gene expression and inducing cancer cell differentiation.
As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signifies potential future developments in drug discovery and treatment for certain cancers. Companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in oncology or hematology research, should be aware of this filing as it may impact their intellectual property landscape and competitive strategies.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
Application US20260085082A1 Kind: A1 Mar 26, 2026
Assignee
Imago Biosciences, Inc.
Inventors
Hugh Y. Rienhoff, Jr., Cassandra Celatka, Amy E. Tapper, Nivedita Namdev, Michael Clare
Abstract
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
CPC Classifications
C07F 9/65583 A61K 31/4155 A61K 31/454 A61K 31/4545 A61K 31/496 A61K 31/541 A61K 31/675 A61K 31/706 A61P 35/02 C07D 231/40 C07D 401/06 C07D 401/12 C07D 401/14 C07D 403/06 C07D 403/10 C07D 403/12 C07D 405/14 C07D 413/14 C07D 417/14 C07D 491/056
Filing Date
2023-12-15
Application No.
19137840
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.